49.38

0.26% 0.13

Pre-market: 49.98 0.60 +1.22%

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $49.38, with a volume of 548.68K. It is up +0.26% in the last 24 hours and down -7.35% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Previous Close:

$49.25

Open:

$48.8

24h Volume:

548.68K

Relative Volume:

0.75

Market Cap:

$2.84B

Revenue:

$718.95M

Net Income/Loss:

$-38.55M

P/E Ratio:

-72.20

EPS:

-0.6839

Net Cash Flow:

$45.99M

1W Performance:

-2.83%

1M Performance:

-7.35%

6M Performance:

+4.84%

1Y Performance:

+51.01%

1-Day Range:

$48.23

$49.87

1-Week Range:

$46.83

$50.48

52-Week Range:

$29.16

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

778

Twitter

@Supernus_Pharma

Next Earnings Date

2024-11-04

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	49.38	2.84B	718.95M	-38.55M	45.99M	-0.6839
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

Mar 23, 2026

Jefferies reiterates Supernus Pharmaceuticals stock Buy rating By Investing.com - Investing.com South Africa

Mar 23, 2026

Jefferies reiterates Supernus Pharmaceuticals stock Buy rating - Investing.com UK

Mar 23, 2026

Mar 22, 2026

Breakout Watch: What is the target price for Supernus Pharmaceuticals Inc stockQuarterly Growth Report & Low Volatility Stock Suggestions - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

SUPN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 21, 2026

The Technical Signals Behind (SUPN) That Institutions Follow - Stock Traders Daily

Mar 21, 2026

SUPN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 21, 2026

Mar 20, 2026

SUPN Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 20, 2026

Mar 18, 2026

Quarterly Risk: Does Supernus Pharmaceuticals Inc have strong EBITDA margins2026 Technicals & High Accuracy Buy Signal Tips - baoquankhu1.vn

Mar 18, 2026

Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock - MarketBeat

Mar 18, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock - MarketBeat

Mar 18, 2026

[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan

Mar 18, 2026

Supernus Pharmaceuticals Q4 2025 earnings preview - MSN

Mar 18, 2026

Mar 17, 2026

SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise - Stock Titan

Mar 17, 2026

SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 17, 2026

Supernus Pharmaceuticals CEO Sells $1.76M in Stock - National Today

Mar 17, 2026

Mar 16, 2026